Biocon Ltd.

BIOCON

Market Cap
₹31,420 Cr.
P/E
26.18

Biocon Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
Company has made significant capex which might be affecting its ROCE
Depreciation Effect
Company is depreciating a greater percentage of assets. This is contributing to a reduction in Net Profit
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Company is converting accounting profit to cash
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been buying the stock which is usually a sign of exuberance
Share price
Share price has increased over last 10 years due to earnings
ROE
Asset Turnover is responsible for ROE increase over last 10 years
Working Capital
Company has significant working capital which is dragging its ROCE and ROE
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a discount to 3 year historic valuations
ROE
Latest
2.59%
3yr Average
6.66%
5yr Average
9.2%
Net Profit Margin
Latest
4.14%
3yr Average
7.48%
5yr Average
10.14%
ROCE
Latest
4.1%
3yr Average
7.0%
5yr Average
9.08%
Debt to Equity
Latest
0.99
3yr Average
0.72
5yr Average
0.59
Market Share
1.52% (as of Jul 22)
Anti - Diabetes - Market Share
0.27% (as of Jul 22)
Anti-Infectives - Market Share
4.21% (as of Nov 21)
Antineo Plastic - Market Share
1.04% (as of Nov 21)
Blood Related - Market Share
27% (as of Mar 19)
CANMAb - Market Share
locked Source
0.05% (as of Jul 22)
Cardiovascular - Market Share
0.16% (as of Nov 21)
Dermatology - Market Share
0.04% (as of Apr 20)
Endocrinology - Market Share
0.01% (as of Jul 22)
Gastro-Intestinal - Market Share
75% (as of Mar 19)
Insugen - Market Share
locked Source
50% (as of Mar 19)
Orlistat API - Market Share
locked Source
0.01% (as of Nov 21)
Pain - Market Share
21% (as of Mar 19)
Pegfi Igrastim Syringes - Market Sharee
locked Source
0.30% (as of Dec 22)
Pharmaceutical Sector - Market Share
30% (as of Mar 20)
Trastuzumab - Market Share
locked Source
0.15% (as of Jul 22)
Vaccines - Market Share
0% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • Domestic Sales Growth - YoY (%)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Brands
    CANMAb
    Insugen
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Biocon Ltd.
    Biocon Biologics Serum Lifesciences collaboration call notes - JST Investments
    View the discussion on ValuePickr
    Industrial Biotechnology - Insulin Production - NPTEL
    How Biocon produces Insulin using rDNA Technology - Bio Science
    Biocon - Viatris Takeover Primer - JST Investments
    Biocon Biologics - An effort to understand the biosimilar business - Dr Midhun
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline